287 related articles for article (PubMed ID: 36793283)
21. Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation.
Cheung KL; Zhang F; Jaganathan A; Sharma R; Zhang Q; Konuma T; Shen T; Lee JY; Ren C; Chen CH; Lu G; Olson MR; Zhang W; Kaplan MH; Littman DR; Walsh MJ; Xiong H; Zeng L; Zhou MM
Mol Cell; 2017 Mar; 65(6):1068-1080.e5. PubMed ID: 28262505
[TBL] [Abstract][Full Text] [Related]
22. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme.
Ye Y; Zhong W; Qian J; Zhang J; Xu T; Han R; Han J; Wang C; Song L; Zeng X; Wang H
Front Cell Dev Biol; 2023; 11():1042490. PubMed ID: 36711038
[No Abstract] [Full Text] [Related]
24. BET proteins are essential for the specification and maintenance of the epiblast lineage in mouse preimplantation embryos.
Tsume-Kajioka M; Kimura-Yoshida C; Mochida K; Ueda Y; Matsuo I
BMC Biol; 2022 Mar; 20(1):64. PubMed ID: 35264162
[TBL] [Abstract][Full Text] [Related]
25. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
Gao Z; Man X; Li Z; Bi J; Liu X; Li Z; Zhu Y; Zhang Z; Kong C
Oncol Rep; 2019 Apr; 41(4):2440-2452. PubMed ID: 30816525
[TBL] [Abstract][Full Text] [Related]
26. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.
Zengerle M; Chan KH; Ciulli A
ACS Chem Biol; 2015 Aug; 10(8):1770-7. PubMed ID: 26035625
[TBL] [Abstract][Full Text] [Related]
27. Physachenolide C is a Potent, Selective BET Inhibitor.
Zerio CJ; Sivinski J; Wijeratne EMK; Xu YM; Ngo DT; Ambrose AJ; Villa-Celis L; Ghadirian N; Clarkson MW; Zhang DD; Horton NC; Gunatilaka AAL; Fromme R; Chapman E
J Med Chem; 2023 Jan; 66(1):913-933. PubMed ID: 36577036
[TBL] [Abstract][Full Text] [Related]
28. BRD4/8/9 are prognostic biomarkers and associated with immune infiltrates in hepatocellular carcinoma.
Chen YR; Ouyang SS; Chen YL; Li P; Xu HW; Zhu SL
Aging (Albany NY); 2020 Sep; 12(17):17541-17567. PubMed ID: 32927435
[TBL] [Abstract][Full Text] [Related]
29. Emerging roles of BET proteins in transcription and co-transcriptional RNA processing.
Eischer N; Arnold M; Mayer A
Wiley Interdiscip Rev RNA; 2023 Jan; 14(1):e1734. PubMed ID: 35491403
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
[TBL] [Abstract][Full Text] [Related]
31. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
Sartor GC; Powell SK; Brothers SP; Wahlestedt C
J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
[TBL] [Abstract][Full Text] [Related]
33. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
Özata DM; Caramuta S; Velázquez-Fernández D; Akçakaya P; Xie H; Höög A; Zedenius J; Bäckdahl M; Larsson C; Lui WO
Endocr Relat Cancer; 2011 Oct; 18(6):643-55. PubMed ID: 21859927
[TBL] [Abstract][Full Text] [Related]
34. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
[TBL] [Abstract][Full Text] [Related]
35. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
36. CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle.
Huang YG; Li D; Wang L; Su XM; Tang XB
J Transl Med; 2022 Feb; 20(1):78. PubMed ID: 35123514
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
38. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.
Klein K; Kabala PA; Grabiec AM; Gay RE; Kolling C; Lin LL; Gay S; Tak PP; Prinjha RK; Ospelt C; Reedquist KA
Ann Rheum Dis; 2016 Feb; 75(2):422-9. PubMed ID: 25467295
[TBL] [Abstract][Full Text] [Related]
39. [Expression of BRD7-interacting proteins,BRD2 and BRD3, in nasopharyngeal carcinoma tissues].
Zhou M; Peng C; Nie XM; Zhang BC; Zhu SG; Yu Y; Li XL; Li GY
Ai Zheng; 2003 Feb; 22(2):123-7. PubMed ID: 12600283
[TBL] [Abstract][Full Text] [Related]
40. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
